These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 7954465)

  • 41. Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia.
    Gregg EO; Bridges SH; Youle RJ; Longo DL; Houston LL; Glennie MJ; Stevenson FK; Green I
    J Immunol; 1987 Jun; 138(12):4502-8. PubMed ID: 3495593
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
    Shen GL; Li JL; Vitetta ES
    J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
    Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
    Blood; 1992 Nov; 80(9):2315-20. PubMed ID: 1384801
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro cytotoxicity of recombinant ricin A chain-antitransferrin receptor immunotoxin against human adenocarcinomas of the colon and pancreas.
    Griffin TW; Pagnini PG; McGrath JJ; McCann JC; Houston LL
    J Biol Response Mod; 1988 Dec; 7(6):559-67. PubMed ID: 3265147
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
    Byers VS; Rodvien R; Grant K; Durrant LG; Hudson KH; Baldwin RW; Scannon PJ
    Cancer Res; 1989 Nov; 49(21):6153-60. PubMed ID: 2790828
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potent cytotoxicity of an antihuman transferrin receptor-ricin A-chain immunotoxin on human glioma cells in vitro.
    Recht LD; Griffin TW; Raso V; Salimi AR
    Cancer Res; 1990 Oct; 50(20):6696-700. PubMed ID: 2208135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of human T-cell tumor growth by T101-ricin A-chain in an athymic mouse model.
    Leonard JE; Johnson DE; Shawler DL; Dillman RO
    Cancer Res; 1988 Sep; 48(17):4862-7. PubMed ID: 3261627
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction.
    Jaffrézou JP; Levade T; Thurneyssen O; Chiron M; Bordier C; Attal M; Chatelain P; Laurent G
    Cancer Res; 1992 Mar; 52(5):1352-9. PubMed ID: 1737397
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
    Conry RM; Khazaeli MB; Saleh MN; Ghetie V; Vitetta ES; Liu T; LoBuglio AF
    J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):231-41. PubMed ID: 8680651
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [In vitro and in vivo antitumor activity of monoclonal anti-MM46 antibody-ricin A chain conjugate].
    Takahashi T; Seto M; Hara T
    Gan To Kagaku Ryoho; 1983 Aug; 10(8):1894-1900. PubMed ID: 6882010
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Covalent binding of human alpha 2-macroglobulin to deglycosylated ricin A chain and its immunotoxins.
    Ghetie MA; Uhr JW; Vitetta ES
    Cancer Res; 1991 Mar; 51(5):1482-7. PubMed ID: 1705175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.
    Tazzari PL; de Totero D; Bolognesi A; Testoni N; Pileri S; Roncella S; Reato G; Stein H; Gobbi M; Stirpe F
    Haematologica; 1999 Nov; 84(11):988-95. PubMed ID: 10553158
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
    Van Horssen PJ; Preijers FW; Van Oosterhout YV; De Witte T
    Int J Cancer; 1996 Nov; 68(3):378-83. PubMed ID: 8903481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
    Schnell R; Staak O; Borchmann P; Schwartz C; Matthey B; Hansen H; Schindler J; Ghetie V; Vitetta ES; Diehl V; Engert A
    Clin Cancer Res; 2002 Jun; 8(6):1779-86. PubMed ID: 12060617
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma.
    Otto M; Barfield RC; Martin WJ; Iyengar R; Leung W; Leimig T; Chaleff S; Gillies SD; Handgretinger R
    Clin Cancer Res; 2005 Dec; 11(23):8486-91. PubMed ID: 16322312
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
    Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
    J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human antibody responses to components of the monoclonal antimelanoma antibody ricin A chain immunotoxin XomaZyme-MEL.
    Mischak RP; Foxall C; Rosendorf LL; Knebel K; Scannon PJ; Spitler LE
    Mol Biother; 1990 Jun; 2(2):104-9. PubMed ID: 2363853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
    Zovickian J; Johnson VG; Youle RJ
    J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins.
    Engert A; Gottstein C; Winkler U; Amlot P; Pileri S; Diehl V; Thorpe P
    Leuk Lymphoma; 1994 May; 13(5-6):441-8. PubMed ID: 8069189
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice.
    Zhong RK; van de Winkel JG; Thepen T; Schultz LD; Ball ED
    J Hematother Stem Cell Res; 2001 Feb; 10(1):95-105. PubMed ID: 11276363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.